Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).-Reference-Cited by-同舟云学术

Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).

Published:2014-05-20 Issue:15_suppl Volume:32 Page:8004-8004
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Yang James Chih-Hsin¹,Sequist Lecia V.²,Schuler Martin H.³,Mok Tony⁴,Yamamoto Nobuyuki⁵,O'Byrne Kenneth John⁶,Hirsh Vera⁷,Geater Sarayut Lucien⁸,Zhou Caicun⁹,Massey Dan¹⁰,Zazulina Victoria¹⁰,Wu Yi-Long¹¹

Affiliation:

1. National Taiwan University Hospital, Taipei, Taiwan

2. Massachusetts General Hospital and Harvard Medical School, Boston, MA

3. Department of Medicine (Cancer Research), West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany

4. The Chinese University of Hong Kong, Hong Kong, China

5. Wakayama Medical University, Wakayama, Japan

6. St. James's Hospital, Dublin, Ireland

7. McGill University, Montreal, QC, Canada

8. Prince of Songkla University, Songkhla, Thailand

9. Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

10. Boehringer Ingelheim Ltd, Bracknell, Berkshire, United Kingdom

11. Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.8004

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I;Critical Reviews in Oncology/Hematology;2024-07

2. Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice;Therapeutic Advances in Medical Oncology;2021-01

3. Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells;Radiation Oncology;2020-03-06

4. Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer;Current Oncology;2018-02-01

5. Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) – Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy;Pathology & Oncology Research;2017-12-21